← Browse by Condition
Medical Condition

advanced renal cell carcinoma

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 2, Phase 2, Phase 4

ClinicalMetric tracks all active clinical trials for advanced renal cell carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — advanced renal cell carcinoma Clinical Trials

How many clinical trials are currently recruiting for advanced renal cell carcinoma?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for advanced renal cell carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for advanced renal cell carcinoma?
advanced renal cell carcinoma research spans Phase 1 (1 trial), Phase 2 (2 trials), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a advanced renal cell carcinoma clinical trial?
Eligibility criteria for advanced renal cell carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
2
Phase 4
1
Top Sponsors
M.D. Anderson Cancer Center 1 trial
Karie Runcie 1 trial
OHSU Knight Cancer Institute 1 trial

Recruiting Clinical Trials

NCT05703854 Phase 1, Phase 2
Recruiting
Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
Enrollment
50 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT06863311 Phase 2
Recruiting
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Enrollment
70 pts
Location
United States
Sponsor
Karie Runcie
View Trial →
NCT07405086 Phase 4
Recruiting
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
Enrollment
160 pts
Location
United States
Sponsor
OHSU Knight Cancer Institute
View Trial →

Related Conditions

metastatic renal cell carcinoma (2) advanced mesothelioma (1) advanced osteosarcoma (1) clear cell renal cell carcinoma (1) advanced biliary tract carcinoma (1) advanced head and neck squamous cell carcinoma (1) advanced hepatocellular carcinoma (1) advanced lung non small cell carcinoma (1) advanced malignant solid neoplasm (1) advanced melanoma (1) metastatic biliary tract carcinoma (1) metastatic head and neck squamous cell carcinoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology